Viramune XR

See also: Generic Viramune

Viramune XR is a brand name of nevirapine, approved by the FDA in the following formulation(s):

VIRAMUNE XR (nevirapine - tablet, extended release; oral)

• 
  Manufacturer: BOEHRINGER INGELHEIM
  
  Approval date: March 25, 2011
  
  Strength(s): 400MG ^[RLD]

Has a generic version of Viramune XR been approved?

No. There is currently no therapeutically equivalent version of Viramune XR available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Viramune XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
  Patent 5,366,972
  Issued: November 22, 1994
  Inventor(s): Hargrave; Karl D. & Proudfoot; John R. & Adams; Julian & Grozinger; Karl G. & Schmidt, deceased; Gunther & Engel; Wolfhard & Trummlitz; Gunther & Eberlein; Wolfgang
  Assignee(s): Boehringer Ingelheim Pharmaceuticals, Inc.
  Disclosed are novel 5,11-dihydro-6H-dipyrido[3,2-b; 2',3'-e][1,4]diazepines. These are useful in the prevention or treatment of HIV infection.
  
  Patent expiration dates:
  
  
  • November 22, 2011
    
    ✓ 
    Patent use: METHOD FOR TREATING HIV-1 INFECTION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • May 22, 2012
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • March 25, 2014 - NEW DOSAGE FORM
  
  

See also...

• Viramune XR Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Viramune XR Consumer Information (Cerner Multum)
• Viramune XR Advanced Consumer Information (Micromedex)
• Nevirapine Consumer Information (Wolters Kluwer)
• Nevirapine Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Nevirapine Suspension Consumer Information (Wolters Kluwer)
• Nevirapine Consumer Information (Cerner Multum)
• Viramune O/S Advanced Consumer Information (Micromedex)
• Nevirapine Advanced Consumer Information (Micromedex)
• Nevirapine AHFS DI Monographs (ASHP)

Fosinoprilnatrium Apotex

Fosinoprilnatrium Apotex may be available in the countries listed below.

Ingredient matches for Fosinoprilnatrium Apotex

Fosinopril

Fosinopril sodium salt (a derivative of Fosinopril) is reported as an ingredient of Fosinoprilnatrium Apotex in the following countries:

• Netherlands

International Drug Name Search

Povidon Iodin Domesco

Povidon Iodin Domesco may be available in the countries listed below.

Ingredient matches for Povidon Iodin Domesco

Povidone Iodine

Povidone-Iodine is reported as an ingredient of Povidon Iodin Domesco in the following countries:

• Vietnam

International Drug Name Search

EFDEGE

EFDEGE may be available in the countries listed below.

Ingredient matches for EFDEGE

Fludeoxyglucose (18F)

Fludeoxyglucose (18F) is reported as an ingredient of EFDEGE in the following countries:

• Luxembourg

International Drug Name Search